CD274 and cholangiocarcinoma: The following global randomized phase 3 studies TOPAZ-1 and KEYNOTE-966 changed practice establishing combination treatment with anti-PD-(L)1 and chemotherapy as the recommended first-line choice for patients with advanced CCA [15,16].